CENEXI is a CDMO for drug products, specializing in compounding, fill and finish of injectables (vials, lyophilized products, pre-filled syringes, and ampoules), hormonal and desensitizing tablets. Cenexi provides industrial development and scale-up for commercial products, as well as clinical batches for Phases 1, 2, and 3. The drug substances compounded and filled include biologics, vaccines, mAbs, ADCs, high-potency products, sex hormones, and regular products.

CENEXI is a one-stop shop for sterile injectables. With a pilot GMP workshop for small and clinical batches, as well as 12 aseptic filling lines, CENEXI is a leading CDMO in Europe.

Chelatec offers preclinical research services dedicated to the development of therapeutic radiopharmaceuticals in oncology.

With state-of-the-art laboratories fully equipped for radiochemistry work, radioanalyses, cell handling and animal housing, Chelatec is recognized for its reliable expertise and offers a unique combination of custom radiolabeling, in vitro assays, and in vivo/ex vivo investigation capabilities.

Backed by 25 years of expertise in dedicated laboratories, Chelatec provides information on Investigational Medicinal Products that can be included in the documentation package: all quality and non-clinical safety data required for the translation of a radiopharmaceutical.

Novalix is a premier contract research organization dedicated to improving the critical early stages of drug discovery by combining exceptional scientific talent and exclusive technology with a comprehensive portfolio of world-class chemistry, biophysics and pharmacology capabilities. Novalix works collaboratively with its clients to meet the most complex scientific challenges, and its innovative partnerships with leading instrument makers and academic institutions help it continually expand the possibilities of human health.

From early discovery to candidate selection, Novalix tailors every project around clients’ needs and goals. Every engagement is driven by experienced scientists using exceptional technology to increase the odds of success at each stage.

Comprehensive capabilities are organized into five centers of excellence: Chemistry, Biophysics, Pharmacology and DMPK, Drug Discovery, and Cosmetics.
A wide range of areas is covered, including medicinal chemistry, cheminformatics, synthetic chemistry, process chemistry and scale-up, biophysics (NMR, MS, SPR), protein production with a focus on GPCRs, and structural biology techniques such as cryo-EM, protein X-ray crystallography, and NMR. Novalix also excels in in vitro and in vivo pharmacology, translational science, biobanking, histology, ADME-DMPK, and pre-formulation.

Scientific expertise includes diverse modalities, such as small molecules, biologics (mAbs, ADCs), and PROTACs. The company focuses on various therapeutic areas, namely oncology, immuno-inflammation, infectious diseases, fibrosis, kidney diseases, osteoarthritis, and metabolic disorders.

State-of-the-art facilities are located in France and Tunisia, with business representative offices in the United States and Japan, ensuring a global presence and reach.

PhInc. Modeling is a Contract Research Organization (CRO) specialized in quantitative pharmacology solutions to support biotechs in the development of drug candidates, new chemical entities, and biological entities. The company relies on the Model-Informed Drug Development (MIDD) approach to make informed decisions supported by analyses and modeling.

This strategy allows PhInc. Modeling to integrate quantitative modeling and simulations to optimize drug development, predict pharmacological responses, and identify the best dosing strategies.

By using mathematical models and simulations, PhInc. Modeling can anticipate the effects of a drug candidate in different populations and conditions, thereby reducing risks and costs associated with clinical development. Through MIDD, the company aims to improve the efficiency of clinical trials and accelerate the market entry of new treatments.

ALPX, an EMBL spin-off, provides comprehensive structural biology services to accelerate drug discovery programs. They specialize in delivering rapid and reliable structural insights for biotech and pharmaceutical partners, leveraging their expertise across X-ray crystallography, cryo-EM, and protein production.
Their core strength lies in their integrated, transparent, and flexible high-throughput protein-to-structure pipelines, designed to address challenging targets and timelines.

• X-ray Crystallography: ALPX offers end-to-end services from protein crystallization to structure determination, including compound and fragment screening. ALPX’s operations are supported by proprietary technologies like CrystalDirect™ and CRIMS and enabled by weekly access to synchrotron beamlines, ensuring swift delivery of high-quality data.

• Cryo-EM: ALPX provides a streamlined workflow from sample preparation and grid screening to data collection and high-resolution structure determination. Their process is supported by collaborations with leading imaging centers and robust cloud-based processing infrastructure, allowing them to manage complex projects efficiently.

• Protein Production: ALPX delivers optimized protein expression and purification services tailored for downstream structural studies. Their deep understanding of diverse protein targets ensures the production of high-quality material, which is a critical foundation for successful structural campaigns.

ALPX has extensive experience in solving structures for challenging targets and complex systems such as large protein complexes, molecular glues and PROTACs, protein-antibody and protein-DNA complexes and membrane proteins. Their automated platforms and deep scientific expertise enable them to deliver structural data with speed and precision, helping their partners advance their projects from early hits to validated lead candidates.